LANSING, Mich., Dec. 21, 2023 /PRNewswire/ -- Neogen Corporation (NASDAQ: NEOG) announced today that the Company will participate in the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Thursday, January 11, 2024.
John Adent, Neogen's President and Chief Executive Officer, will present at 9:00 a.m. Pacific Time.
To access the webcast and presentation materials, please visit the Events & Presentations section of the Neogen Investor Relations website at neogen.com/investor-relations/events-presentations and click on the event webcast link.
About Neogen
Neogen Corporation is committed to fueling a brighter future for global food security through the advancement of human and animal well-being. Harnessing the power of science and technology, Neogen has developed comprehensive solutions spanning the Food Safety, Livestock, and Pet Health & Wellness markets. A world leader in these fields, Neogen has a presence in over 140 countries with a dedicated network of scientists and technical experts focused on delivering optimized products and technology for its customers.
Contact
Bill Waelke — VP, IR & Treasury
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$5.88 |
Daily Change: | -0.05 -0.84 |
Daily Volume: | 2,919,793 |
Market Cap: | US$1.280B |
May 13, 2025 January 21, 2025 January 10, 2025 December 17, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load